Alder BioPharmaceuticals® to Present at the 2018 Bank of America Merrill Lynch Health Care Conference

BOTHELL, Wash., May 07, 2018 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Paul B. Cleveland, Interim President and Chief

Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine

Patients with a 75% or greater response experienced an eight-fold increase in migraine-free days and more meaningful improvements in bodily pain and physical function BOTHELL, Wash., April 25, 2018 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic

Alder BioPharmaceuticals® Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine

– Data presented at AAN Annual Meeting demonstrate eptinezumab further reduces migraine risk following the third and fourth quarterly infusions – More than 50% of patients achieved a 75% reduction or greater of migraine days BOTHELL, Wash., April 24, 2018 (GLOBE NEWSWIRE)

Alder BioPharmaceuticals® Appoints Eric Carter, Ph.D., M.D., as Interim Chief Medical Officer

BOTHELL, Wash., April 23, 2018 (GLOBE NEWSWIRE) — Alder Biopharmaceuticals, Inc., (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Eric Carter, Ph.D., M.D., has been named Interim Chief Medical Officer, effective immediately. His primary